PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

OARSI 2024, page-93

  1. 1,116 Posts.
    lightbulb Created with Sketch. 212
    There is a huge amount of doubt at the moment about FDA approval, will there be non dilutive funding or a CR at a big discount.
    If all of those doubts are dismissed I have no doubt there will be a positive rerate.
    We live in hope
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.